## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of antiβdementia drugs. However, there is limited information available regarding the bioβmedical aspects of the differing drugs; particularly relating to adults with intellectual disability
Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome
β Scribed by V. P. Prasher; N. Fung; C. Adams
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 38 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-6230
- DOI
- 10.1002/gps.1306
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
End-stage dementia in adults with Down syndrome has not been fully investigated. Available information, 6 months prior to death, for 20 adults with Down syndrome who had died with Alzheimer's disease was reviewed. A terminal stage of severe intellectual deterioration, marked personality and mood cha
## Abstract ## Objectives To investigate the relation of plasma levels of A__Ξ²__ peptides (A__Ξ²__1β40 and A__Ξ²__1β42) and apolipoprotein E (APOE) genotype to dementia status, and the duration of Alzheimer's disease (AD) in adults with Down syndrome (DS). ## Methods Adults with DS were recruited